8-azaguanine (5-amino-7-hydroxy-1H-v-triazolo [d] pyrimidine) had a definite inhibitory effect on the growth of mammary adenocarcinoma E0 771; however, it had no complete destructive action upon this tumor.
The inhibition was most apparent when the compound was administered early in the development of the tumor. There was little or no effect on adenocarcinoma E0 771 if treatment was delayed until 6 days after transplantation.
Spontaneous mammary cancers in C3H (Bar Harbor) and in Swiss mice (Rockland Farms) were apparently unaffected by repeated injections of 8-azaguanine.
The use of 8-azaguanine in the treatment of mice bearing Sarcoma 180, sarcoma T241, Harding-Passey melanoma, Wagner osteogenic sarcoma, or Patterson lymphosarcoma, and of rats bearing Flexner-Jobling carcinoma, Sarcoma R39, or Walker carcino-sarcoma 256, produced neither an inhibitory nor a curative effect upon these tumors.
Repeated intraperitoneal injections of 8-azaguanine into C57 black mice bearing adenocarcinoma E0 771 produced extensive gelatinous edema in the subcutaneous tissues and tissues of the thoracic and abdominal walls, and intraperitoneal hemorrhage and ascites. These changes were less pronounced in albino mice and were absent in albino rats.
This work was supported from a grant by the Charles F. Kettering Foundation to the Wellcome Research Laboratories and by a grant to the Sloan-Kettering Institute from the American Cancer Society.